Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by VectivBio AG
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
June 26, 2023
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio Publishes Invitation to the Annual General Meeting
May 10, 2023
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
April 19, 2023
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023
April 12, 2023
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
March 13, 2023
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio Announces Results of Extraordinary General Meeting
December 09, 2022
From
VectivBio AG
Via
GlobeNewswire
Tickers
FRBN
NAMS
VECT
VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders
November 16, 2022
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
November 09, 2022
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)
November 03, 2022
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares
October 18, 2022
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
October 13, 2022
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)
October 13, 2022
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
VectivBio Announces Date of Extraordinary General Meeting of Shareholders
October 12, 2022
From
VectivBio AG
Via
GlobeNewswire
Tickers
VECT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.